Alliance for Regenerative Medicine

Tweet this page
Registration as it was on 21 Dec 2023
How to read and use this data card.
Download this datacard


Lobbying Costs

400,000€ - 499,999€

Financial year: Jan 2022 - Dec 2022

Lobbyists (Full time equivalent)

2 Fte (4)

Lobbyists with EP accreditation


High-level Commission meetings


Lobbying Costs over the years

  • Info

    Alliance for Regenerative Medicine   (ARM)

    EU Transparency Register

    244710319190-73 First registered on 14 Oct 2015

    Goals / Remit

    The Alliance for Regenerative Medicine (ARM, is the international advocacy organization dedicated to realizing the promise of advanced therapy medicinal products (ATMPs). ARM promotes legislative, regulatory, reimbursement and manufacturing initiatives in Europe and globally to advance this innovative and transformative sector, which includes cell and gene therapies, and tissue-based therapies. ARM is the global voice of the sector, representing 400+ members worldwide, including SMEs, large companies, academic research institutions, major medical centres and patient groups.

    Main EU files targeted

    ARM is interested in following any legislative or policy initiative on advanced therapies, including on broader aspects which may have an impact on advanced therapies such as initiatives on pharmaceuticals, blood, tissues and cells, clinical trials, orphan medicines, health technology assessment, health data, cross-border healthcare. ARM is also interested in initiatives and policy developments relating to small and medium size enterprises and access to capital.


    Head Office
    1015 18th Street NW Suite 1102
    Washington DC 20036
    EU Office
    Rue de L'Industrie 24
    Brussels 1040


  • People

    Total lobbyists declared


    Employment timeLobbyists

    Lobbyists (Full time equivalent)


    Lobbyists with EP accreditation

    All Lobbyists with EP accreditation over time

    0 accreditations were / are live (in bold) for the selected state of 19 Jul 2024

    Name Start date End Date
    Elisabetta ZANON 13 May 2023 11 May 2024
    Elisabetta ZANON 24 May 2022 13 May 2023

    Complementary Information

    None declared

    Person in charge of EU relations

    Data not provided by Register Secretariat due to GDPR

    Person with legal responsibility

    Data not provided by Register Secretariat due to GDPR

  • Categories


    Non-governmental organisations, platforms and networks and similar

  • Networking


    Standards Coordinating Body for Gene, Cell and Regenerative Medicines and Cell-Based Drug Discovery

    Foundation for Cell and Gene Medicine

    National Academy of Sciences Forum on Regenerative Medicine

    Member organisations

    None declared

  • Financial Data

    Interests represented

    Promotes their own interests or the collective interests of their members

    Closed financial year

    Jan 2022 - Dec 2022

    Lobbying costs for closed financial year

    400,000€ - 499,999€

    Major contributions in closed year

    None declared

    Intermediaries for closed year

    finsbury glover schuppener global 300,000€ - 399,999€

    Intermediaries for current year

    covington & burling llp
    harwood levitt consulting
    apco worldwide

    Closed year Costs

    400,000€ - 499,999€

    Other financial info

    None declared

  • EU Structures

    Groups (European Commission)


    Groups (European Parliament)


    Communication activities

    As part of its activities, ARM releases policy recommendations, policy papers and reports. ARM produces regular reports providing an overview of the sector including data on clinical trial, therapeutic developers and investment in the sector. ARM also publishes a newsletter for its members where regulatory, legislative and policy developments in Europe and elsewhere are reported. ARM organizes an annual meeting on advanced therapies in Europe, named the Cell & Gene Meeting on the Mediterranean. See more on

    Other activities

    None declared

  • Meetings


    3 meetings found. Download meetings

    The list below only covers meetings held since November 2014 with commissioners, their cabinet members or directors-general at the European Commission; other lobby meetings with lower-level staff may have taken place, but the European Commission doesn't proactively publish information about these meetings. For more information about which commissioner is responsible for which portfolio, check out this link: All information below comes from European Commission web pages.

    1 July 2024: We have noted that some meetings are appearing in duplicate, ie. some meetings seem to be listed twice. This seems to be because the Commission changes some element of a meeting data after the meeting has first been listed, which causes LobbyFacts to register it as a new meeting. We are investigating further.

    • Date 19 Sep 2023 Location Brussels, Belgium
      Subject Exchange of views with the Alliance for Regenerative Medicine on the implementation of the HTA Regulation as well as the reform of the EU Pharmaceutical Legislation.
      Cabinet Cabinet of Commissioner Stella Kyriakides
      Portfolio Health
      • Karolina Herbout-Borczak (Cabinet member)
    • Date 27 Jan 2022 Location Brussels, virtual
      Subject Exchanges of views on policy priorities of the Alliance for Regenerative Medicine in Europe: the Pharmaceutical Strategy and the EU’s Beating Cancer Plan
      Cabinet Cabinet of Commissioner Stella Kyriakides
      Portfolio Health
      • Karolina Herbout-Borczak (Cabinet member)
    • Date 08 Nov 2017 Location Brussels
      Subject Advanced therapy medicinal products
      Cabinet Cabinet of Commissioner Vytenis Andriukaitis
      Portfolio Health &amp; Food Safety
      • Annika Nowak (Cabinet member)
Download this datacard